Arrakis Therapeutics
Arrakis Therapeutics's Overview
Arrakis Therapeutics is at the forefront of discovering and developing a new class of medicines that directly target RNA. Utilizing its proprietary platform, the company aims to create orally administered small molecules (rSMs) to treat a broad spectrum of diseases, including cancer, neurological disorders, and rare genetic conditions. Arrakis is committed to transforming a new area of biology into a source of novel therapeutics for patients.
Where is Arrakis Therapeutics's Headquarters?
HQ Function
Serves as the central hub for research and development, corporate operations, and strategic decision-making for the company's RNA-targeted small molecule platform.
Notable Features:
State-of-the-art laboratory facilities designed for cutting-edge biopharmaceutical research, including capabilities for RNA biology, chemistry, and drug discovery.
Work Culture:
A dynamic, innovative, and collaborative environment focused on scientific excellence and translating groundbreaking research into novel medicines. Emphasis on teamwork and a patient-centric approach.
HQ Significance:
Strategically located in the Boston-Cambridge biotech hub, providing access to a rich ecosystem of talent, research institutions, and potential collaborators, crucial for advancing its pioneering RNA-targeted therapies.
Values Reflected in HQ: The facility reflects Arrakis's commitment to scientific rigor, innovation, and the pursuit of transformative therapies, with spaces designed to foster collaboration and discovery.
Location:
Arrakis Therapeutics, while headquartered in the U.S., establishes global impact through strategic collaborations with international pharmaceutical partners to advance its RNA-targeted therapies. Its research and development efforts aim to address diseases affecting global patient populations, with potential for international clinical trials for its drug candidates.
Street Address:
35 Gatehouse Drive
City:
Waltham
State/Province:
Massachusetts
Country:
United States
Arrakis Therapeutics's Global Presence
N/A
Address: N/A
Operations are focused at the main headquarters.
Buying Intent Signals for Arrakis Therapeutics
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Arrakis Therapeutics
As of April 2025, Arrakis Therapeutics' leadership includes:
Investors of Arrakis Therapeutics
Arrakis Therapeutics has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Over the last 12 months, Arrakis Therapeutics has strengthened its leadership with key appointments including a new Chief Business Officer and a Senior Vice President, Head of Legal. Additionally, the company promoted its then SVP, Head of Platform and Discovery Biology to Chief Scientific Officer. In early 2024, Arrakis implemented a strategic workforce reduction to optimize resources for its pipeline advancement.
New Appointments:
Technology (Tech Stack) used by Arrakis Therapeutics
Discover the tools Arrakis Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Arrakis Therapeutics Email Formats and Examples
Arrakis Therapeutics likely follows common corporate email patterns for biotechnology companies. The most probable format is [first_initial][last]@[companydomain.com], for example, jsmith@arrakis-tx.com.
flast@arrakis-tx.com
Format
mgilman@arrakis-tx.com
Example
90%
Success rate
News and media
Fierce Biotech • February 1, 2024
Arrakis Therapeutics news title: Arrakis trims 20% of workforce to sharpen focus as RNA degrader pushes to clinic
Arrakis Therapeutics laid off approximately 20% of its workforce, reducing its headcount to about 80 employees. The restructuring aims to extend its cash runway and prioritize resources on advancing its lead programs towards clinical development....more
Arrakis Therapeutics Press Release • January 24, 2024
Arrakis Therapeutics news title: Arrakis Therapeutics Promotes Kathleen Meyer, Ph.D., to Chief Scientific Officer
Arrakis Therapeutics announced the promotion of Kathleen Meyer, Ph.D., to Chief Scientific Officer (CSO). Dr. Meyer, previously SVP, Head of Platform and Discovery Biology, will now spearhead the company's comprehensive research strategy and its execution....more
Arrakis Therapeutics Press Release • October 18, 2023
Arrakis Therapeutics news title: Arrakis Therapeutics Completes $50 Million Series C Financing
Arrakis Therapeutics announced the completion of a $50 million Series C financing round. The proceeds will be used to advance its pipeline of RNA-targeted small molecules (rSMs) into clinical development and further enhance its rSM discovery platform....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Arrakis Therapeutics, are just a search away.